MacuLogix Launches the AdaptDx in Europe

MacuLogix will launch the AdaptDx in Europe during its debut at the European Society of Retina Specialists (EURETINA) annual congress in Vienna, Austria.

The AdaptDx is the first commercially available dark adaptometer that can be used in clinical practice to detect AMD at a subclinical stage, before structural changes in the retina like drusen become visible, according to a company news release. As part of the introduction to its technology at EURETINA, MacuLogix will be hosting a series of “Meet the Expert” sessions at booth C623, where renowned ophthalmologists including David Gaucher, MD, (France), Robin Hamilton, MD, (United Kingdom), Michael Larsen, MD, (Denmark), Anat Lowenstein, MD, (Israel), and Jordi Mones, MD, PhD (Spain), will discuss their experience diagnosing subclinical AMD and monitoring disease progression using AdaptDx.

“Introducing the AdaptDx to the European eyecare community during EURETINA is a major milestone for our company,” William McPhee, president and CEO of MacuLogix, said in a company news release. “Our technology and support can enable earlier diagnosis of age-related macular degeneration, when intervention and treatment are most effective. Not only can the routine use of the AdaptDx help prevent blindness caused by AMD, we also believe it has the potential to relieve the societal costs associated with preventable vision loss in an aging population.”

Research has shown that functional assessment of dark adaptation using the AdaptDx can improve diagnostic sensitivity and specificity by detecting the disease with 90% accuracy at least 3 years before drusen are visible, enabling clinicians to intervene before irreversible vision loss occurs.